# RTX-224 Monotherapy in Patients With Solid Tumors

> **NCT05219578** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rubius Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Cutaneous Melanoma
- Head and Neck Squamous Cell Carcinoma
- Urothelial Carcinoma
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** RTX-224

## Key facts

- **NCT ID:** NCT05219578
- **Lead sponsor:** Rubius Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-12
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22. RTX-224 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared rapidly (w/in 10 min).
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05219578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05219578, "RTX-224 Monotherapy in Patients With Solid Tumors". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05219578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*